Publication Describes Work Pertaining to the Cooperative Research and
Development Agreement (CRADA) between the National Institutes of
Health (NIH) and Kite Pharma
Kite Pharma Has an Exclusive License from NIH to Multiple T Cell
Receptor (TCR) Product Candidates Targeting Mutant KRAS to Treat Solid
Research and Accompanying Editorial by Carl H. June, M.D., Published
in the December 8, 2016 New England Journal of Medicine (NEJM)
SANTA MONICA, Calif.--(BUSINESS WIRE)--
Kite Pharma, Inc. (Nasdaq:KITE)
announced today that characterizations of T cell receptor candidates
which it has licensed under the Cooperative Research and Development
Agreement (CRADA) with the National Institutes of Health (NIH) have been
published in the December 8, 2016 New England Journal of Medicine (NEJM).
The research, led by Steven A. Rosenberg, M.D., Ph.D., chief of the
Surgery Branch at NCI's Center for Cancer Research, and a scientific
collaborator with Kite, describes a patient with KRAS mutant metastatic
colorectal cancer who was successfully treated with T cells that are
reactive to KRAS G12D mutation. This work follows previously reported
treatment of a patient with advanced cholangiocarcinoma with T cells
targeting a mutated erbb2 interacting protein.
"We are very excited to see the results of this landmark study conducted
by Dr. Rosenberg and his team at the NCI. These findings represent proof
of concept that T-cell technology directed against neoantigens can be
utilized to treat solid tumors," said David Chang, M.D., Ph.D.,
Executive Vice President, Research and Development, and Chief Medical
Officer of Kite.
As published in the NEJM publication, mutations in the KRAS gene are
thought to drive 95 percent of all pancreatic cancers and 45 percent of
all colorectal cancers. The G12D mutation is the most common KRAS
mutation and is estimated to occur in more than 50,000 new cases of
cancer in the United States each year.
In September 2016, Kite announced that it had entered into an exclusive,
worldwide license with NIH for intellectual property related to multiple
TCR-based product candidates for the treatment of tumors expressing
mutated KRAS antigens. These TCR product candidates were developed in
the laboratories of Steven A. Rosenberg, M.D., Ph.D., and James C. Yang,
M.D., of the NCI.
About Kite Pharma
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged
in the development of novel cancer immunotherapy products, with a
primary focus on engineered autologous cell therapy (eACT™) designed to
restore the immune system's ability to recognize and eradicate tumors.
Kite is based in Santa Monica, CA. For more information on Kite Pharma,
please visit www.kitepharma.com.
Sign up to follow @KitePharma on Twitter at www.twitter.com/kitepharma.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. The press release may, in some cases, use terms such as
"predicts," "believes," "potential," "proposed," "continue,"
"estimates," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "will," "should" or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include
statements regarding intentions, beliefs, projections, outlook, analyses
or current expectations concerning, among other things: the ability to
advance and the success of TCR-based product candidates directed against
KRAS antigens. Various factors may cause differences between Kite's
expectations and actual results as discussed in greater detail in Kite's
filings with the Securities and Exchange Commission, including without
limitation in its Form 10-Q for the quarter ended September 30, 2016.
Any forward-looking statements that are made in this press release speak
only as of the date of this press release. Kite assumes no obligation to
update the forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this press
View source version on businesswire.com: http://www.businesswire.com/news/home/20161212005345/en/
SVP, Corporate Communications &
VP, Investor Relations
Source: Kite Pharma, Inc.
News Provided by Acquire Media